Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
On January 30, the U.S. Food and Drug Administration approved suzetrigine for the treatment of moderate to severe pain in adults. The oral drug, called Journavx, is meant to ease short-term pain, the type that follows tissue injury, such as after surgery. The first of a new class of pain therapies to be approved in decades, the drug doesn’t pose a risk of addiction as opioid medications do, evidence suggests.
.email-conversion { border: 1px solid #ffcccb; color: white; margin-top: 50px; background-image: url(“/wp-content/themes/sciencenews/client/src/images/[email protected]”); padding: 20px; clear: both; }